11 results
Search Results
Now showing 1 - 10 of 11
Publication Metadata only Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients(2014-01-01) Sutima Luangdilok; Norasate Samarnthai; Krittiya Korphaisarn; Mahidol Universityin locally advanced breast cancer. Methods: Medical records of patients who had undergone neoadjuvant chemotherapy for breast cancer between January 2007 and September 2011 were retrospectively reviewed, and the pCR rates were calculated according to three...adjuvant chemotherapy, 167 patients (93.3%) had locally advanced breast cancer and 12 patients (6.7%) had early-stage breast cancer. The majority of patients (152 patients, 89.4%) received anthracycline-based neoadjuvant chemotherapy. The objective clinical responsePublication Metadata only Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A clinical trial(2018-07-01) Melanie Royce; Thomas Bachelot; Cristian Villanueva; Mustafa Özgüroglu; Sergio J. Azevedo; Felipe Melo Cruz; Marc Debled; Roberto Hegg; Tatsuya Toyama; Carla Falkson; Joon Jeong; Vichien Srimuninnimit; William J. Gradishar; Christina Arce; Antonia Ridolfi; Chinjune Lin; Fatima Cardoso; Champalimaud Foundation; Yonsei University Health System; University of New Mexico; Istanbul Üniversitesi; Centre Hospitalier Universitaire de Besancon; The University of Alabama at Birmingham; Le Centre Régional de Lutte Contre le Cancer Léon Bérard; Hospital de Clinicas de Porto Alegre; Novartis Pharma S.A.S.; Northwestern University Feinberg School of Medicine; Faculty of Medicine, Siriraj Hospital, Mahidol University; Universidade de Sao Paulo - USP; Institut Bergonie; Nagoya University; Novartis Pharmaceuticals Corporation; Instituto Brasileiro de Controle do Câncer© 2018 American Medical Association. IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. OBJECTIVE... To investigate the combination of everolimus plus endocrine therapy in first-line and second-line treatment settings for postmenopausal women with estrogen receptor-positive, human epidermal growth receptor 2-negative advanced breast cancer. DESIGN, SETTINGPublication Metadata only Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2(2013-01-01) Kathleen I. Pritchard; Howard A. Burris; Yoshinori Ito; Hope S. Rugo; Shaker Dakhil; Gabriel N. Hortobagyi; Mario Campone; Tibor Csöszi; José Baselga; Puttisak Puttawibul; Martine Piccart; Daniel Heng; Shinzaburo Noguchi; Vichien Srimuninnimit; Hugues Bourgeois; Antonio Gonzalez Martin; Karen Osborne; Ashok Panneerselvam; Tetiana Taran; Tarek Sahmoud; Michael Gnant; University of Toronto; Sarah Cannon Research Institute; Cancer Institute Hospital of Japan Foundation for Cancer Research; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Center of Kansas; University of Texas MD Anderson Cancer Center; Centre de Recherche en Cancérologie; Hetenyi Geza County Hospital; Memorial Sloan-Kettering Cancer Center; Prince of Songkla University; Institut Jules Bordet; University of Calgary; Osaka University; Mahidol University; Centre Jean Bernard; MD Anderson Cancer Center, Madrid; Novartis International AG; Novartis Pharmaceuticals Corporation; Medizinische Universitat Wienwith HR+advanced breast cancer recurring/progressing after treatment with NSAIs. Safety and efficacy data in elderly patients are reported at 18-month median follow-up. Results Baseline disease characteristics and treatment histories among the elderly... deaths. Conclusion Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR+advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE managementItem Metadata only Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand(2024-12-01) Dajsakdipon T.; Susiriwatananont T.; Wongkraisri C.; Ithimakin S.; Parinyanitikul N.; Supavavej A.; Dechaphunkul A.; Sunpaweravong P.; Neesanun S.; Akewanlop C.; Dejthevaporn T.; Dajsakdipon T.; Mahidol UniversityBackground: The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors... (CDK4/6i). Direct comparison trials of different CDK4/6i are scarce. This real-world study compared the effectiveness of first-line AI plus ribociclib versus palbociclib. Methods: This multicenter retrospective cohort study, conducted in six cancerPublication Metadata only Impact of Obesity on Outcomes of Operable Breast Cancer: A Retrospective Cohort Study(2020-04-01) Tanapat Engkakul; Nuntakorn Thnogtang; Akarin Nimmannit; Suebwong Chuthapisith; Charuwan Akewanlop; Faculty of Medicine, Siriraj Hospital, Mahidol UniversityOBJECTIVE: Obesity is increasing worldwide. Previous studies of the impact of obesity on breast cancer outcomes have reported conflicting results. We investigated the association of obesity and breast cancer survival in Thai patients. METHODS...: Medical records of operable breast cancer patients diagnosed and treated at Siriraj Hospital between January 2004 and December 2011 were reviewed. Demographic data, tumor characteristics, stage, treatment and adverse event were described. ObesityPublication Metadata only Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (review)(2008-10-01) Suebwong Chuthapisith; Jennifer M. Eremin; Oleg Eremin; University of Nottingham; Mahidol University; Lincoln County HospitalThe ability to predict the response to neoadjuvant chemotherapy (NAC) prior to or shortly after commencing treatment, in women with large or locally advanced breast cancers, would not only prevent patients from experiencing unnecessary drug... profiling, introduced into clinical practice, have produced preliminary promising results. We describe and discuss these molecular characteristics and approaches and their applications to NAC in breast cancer management.Publication Metadata only SLC35B2 expression is associated with a poor prognosis of invasive ductal breast carcinoma(2014-01-01) Anongruk Chim-Ong; Charin Thawornkuno; Porntip Chavalitshewinkoon-Petmitr; Phaibul Punyarit; Songsak Petmitr; Mahidol University; Army Institute of PathologyBackground: Breast cancer is the most common malignancy in women worldwide, including Thailand, and is a major cause of mortality and morbidity, despite advances in diagnosis and treatment. Novel gene expression in breast cancer is a focus... in searches for prognostic biomarkers and new therapeutic targets. Materials and Methods: The mRNA expression of novel B4GALT4, SLC35B2, and WDHD1 genes in breast cancer were examined in invasive ductal breast carcinoma (IDC) patients using quantitative realPublication Metadata only Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8(2018-02-27) Rochanawan Sootichote; Peti Thuwajit; Ekapot Singsuksawat; Malee Warnnissorn; Pa thai Yenchitsomanus; Suthinee Ithimakin; Jomjit Chantharasamee; Chanitra Thuwajit; Faculty of Medicine, Siriraj Hospital, Mahidol University© 2018 The Author(s). Background: Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines... associated with cancer chemoresistance. This study aims to explore the effect of TLR4 in PTX resistance in triple-negative BCA and advanced melanoma and the effect of compound A (CpdA) to attenuate this resistance. Methods: BCA and melanoma cell lines werePublication Metadata only High ASMA+ Fibroblasts and Low Cytoplasmic HMGB1+ Breast Cancer Cells Predict Poor Prognosis(2017-10-01) Kamolporn Amornsupak; Pranisa Jamjuntra; Malee Warnnissorn; Pornchai O-Charoenrat; Doonyapat Sa-nguanraksa; Peti Thuwajit; Suzanne A. Eccles; Chanitra Thuwajit; Mahidol University; The Institute of Cancer Research, Londonin several cancers, although their roles in breast cancer are unclear. The present study aimed to determine the levels and prognostic significance of α-smooth muscle actin-positive (ASMA+) CAFs, plus HMGB1 and receptor for advanced glycation end products... expression. The levels of ASMA (hazard ratio, 14.162; P =.010) and tumor cytoplasmic HMGB1 (hazard ratio, 0.221; P =.005) could serve as independent prognostic markers for metastatic relapse in breast cancer patients. The ASMA-high/HMGB1-low profile providedItem Metadata only Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors(2022-03-01) Sawasdee N.; Wattanapanitch M.; Thongsin N.; Phanthaphol N.; Chiawpanit C.; Thuwajit C.; Yenchitsomanus P.T.; Panya A.; Mahidol UniversityBreast cancer (BC) is the most common cancer in women. Although standard treatments are successful in patients with BC diagnosed at an early stage, an alternative treatment is required for patients with advanced-stage disease who do not respond... to these treatments. The concept of using chemotherapy to sensitize cancer cells to become susceptible to immunotherapy was recently introduced and may be used as an alternative treatment for BC. The chemotherapeutic drug doxorubicin has been reported to sensitize